• Accueil >
  • Publications >
  • The 21-gene Recurrence ScoreĀ® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

The 21-gene Recurrence ScoreĀ® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

1 dƩc. 2018BMC Cancer

DOI : 10.1186/s12885-018-4331-8

Auteurs

FrƩdƩrique Penault-Llorca, Thomas Filleron, Bernard Asselain, Frederick L. Baehner, Pierre Fumoleau, Magali Lacroix-Triki, Joseph M. Anderson, Carl Yoshizawa, Diana B. Cherbavaz, Steven Shak, Lise Roca, Christine Sagan, JƩrƓme Lemonnier, Anne-Laure Martin, Henri RochƩ